• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    7/17/25 8:31:05 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STXS alert in real time by email
    false 0001289340 0001289340 2025-07-17 2025-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT PURSUANT

     

    TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): July 17, 2025

     

    STEREOTAXIS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

     

    001-36159   94-3120386

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    710 North Tucker Boulevard, Suite 110, St. Louis, Missouri   63101
    (Address of Principal Executive Offices)   (Zip Code)

     

    (314) 678-6100

    (Registrant’s Telephone Number, Including Area Code)

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Securities registered pursuant to Section 12(b) of the Act: ☐

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   STXS   NYSE American LLC

     

     

     

     

     

     

    Item 2.02Results of Operations and Financial Condition.

     

    The Company expects to report revenue for 2025 second quarter in the range of $8.5 million to $8.8 million, reflecting growth of approximately 15% sequentially over its 2025 first quarter and 90% on a year-over-year basis compared to the 2024 second quarter, with growth in both recurring and system revenues. Gross margins for both system and recurring revenue in the second quarter are expected to be at or slightly above levels reported in the first quarter of 2025. GAAP operating expenses are expected to be between $8.2 million and $8.8 million.

     

    The preliminary financial information included in this report is based on the Company’s current expectations and may be adjusted as a result of, among other things, the completion of customary quarter-end close review procedures and financial review. The Company will report its financial results for the period ending June 30, 2025. Its earnings call for the 2025 second quarter is expected to be held in August 2025. See also “Cautionary Note Regarding Forward-Looking Statements” below.

     

    In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 8.01Other Information.

     

    The select preliminary unaudited financial information for the second quarter ended June 30, 2025 reported under Item 2.02 is hereby incorporated by reference herein.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s preliminary results for the 2025 second quarter. These statements are based on current expectations, estimates and projections about the second quarter of 2025 and the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      STEREOTAXIS, INC.
         
    Date: July 17, 2025 By: /s/ Kim Peery
      Name: Kim Peery
      Title: Chief Financial Officer

     

     

     

     

    Get the next $STXS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $STXS

    DatePrice TargetRatingAnalyst
    1/10/2024$5.00Buy
    ROTH MKM
    7/12/2022$6.00Buy
    Aegis Capital
    6/23/2022$6.00Buy
    B. Riley Securities
    1/5/2022$11.00Buy
    Craig-Hallum
    1/5/2022$13.00Buy
    Loop Capital
    More analyst ratings

    $STXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/11/25 3:38:02 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/10/25 10:32:20 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      8/20/24 8:38:24 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    SEC Filings

    See more
    • SEC Form 424B5 filed by Stereotaxis Inc.

      424B5 - Stereotaxis, Inc. (0001289340) (Filer)

      7/18/25 8:36:05 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Stereotaxis, Inc. (0001289340) (Filer)

      7/17/25 8:56:53 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Stereotaxis, Inc. (0001289340) (Filer)

      7/17/25 8:31:05 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Stereotaxis with a new price target

      ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00

      1/10/24 8:16:33 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aegis Capital initiated coverage on Stereotaxis with a new price target

      Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

      7/12/22 9:20:32 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities initiated coverage on Stereotaxis with a new price target

      B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

      6/23/22 8:13:15 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Financials

    Live finance-specific insights

    See more
    • Stereotaxis Reports 2025 First Quarter Financial Results

      ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

      5/12/25 4:01:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

      ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call  When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) a

      4/22/25 7:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Reports 2024 Full Year Financial Results

      ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2024. "We have started a milestone rich year in which we will demonstrate the tangible reality of our overall strategic transformation into a company with an easily adopted robot that can navigate a proprietary set of catheters in EP and broadly across endovascular procedures," said David Fischel, Chairman and CEO. "Our progress leads to an expanded clinical impact, scalable capital model, strategic self-sufficiency, and an attractiv

      3/3/25 7:30:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/24 4:26:22 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/23 4:32:50 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/22 5:07:16 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shamir Nachum was granted 43,668 shares, increasing direct ownership by 96% to 89,276 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      7/3/25 4:05:24 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Benfer David was granted 43,668 shares, increasing direct ownership by 10% to 468,924 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      7/3/25 4:05:27 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Levin Ross B was granted 43,668 shares, increasing direct ownership by 9% to 531,197 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      7/3/25 4:05:30 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

      Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at a price per share of $2.00. The financing is being led by a strategic industry partner along with participation from a select group of institutional investors. "We appreciate the

      7/17/25 8:32:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

      ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled "First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter," the publication is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis' MAGiC catheter. "We are delighted to see the strong efficacy and safety profile of MAGiC published in a prestigious journal," said David Fischel, Stereotaxis Chairman and

      7/1/25 9:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Reports 2025 First Quarter Financial Results

      ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

      5/12/25 4:01:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

      ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The

      10/21/24 8:41:13 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

      ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti

      7/18/24 4:13:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

      ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, the global leader and pioneer of robotic surgery. Dr. Curet joined Intuitive Surgical in 2005 and has since led the development of clinical evidence, physician education, and reimbursement and regulatory activities that have been instrumental to Intuitive Surgical's growth across multiple clinical specialties. For more than 20 years, Dr. Cu

      7/26/21 9:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care